SUPPLEMENT
Q4 2025 — Other Financial Disclosures
Q4 2025PDF · 17 pages590 KB
Table 1: Sales by Segment 1 Table 2: Sales by Geographic Area 2 Table 3: Sales of Key Products/Franchises 3 - 7 Table 4: Condensed Consolidated Statement of Earnings - QTD 8 Table 5: Condensed Consolidated Statement of Earnings - YTD 9 Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 10 Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 11 Table 8: Non-GAAP Adjusted Net Earnings 12 Table 9: Non-GAAP P&L by Segment Reconciliation 2025 - QTD 13 Table 10: Non-GAAP P&L by Segment Reconciliation 2024 - QTD 14 Table 11: Non-GAAP P&L by Segment Reconciliation 2025 - YTD 15 Table 12: Non-GAAP P&L by Segment Reconciliation 2024 - YTD 16 Fourth Quarter 2025 Other Financial Disclosures Table of Contents -- 1 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2025 2024 Total Operations Currency 2025 2024 Total Operations Currency Sales to customers by segment of business Innovative Medicine U.S. 9,689 $ 8,977 7.9 % 7.9 - 36,344 $ 33,970 7.0 % 7.0 - International 6,074 5,355 13.4 7.9 5.5 24,057 22,994 4.6 2.9 1.7 15,763 14,332 10.0 7.9 2.1 60,401 56,964 6.0 5.3 0.7 MedTech U.S. 4,506 4,227 6.6 6.6 - 17,408 16,332 6.6 6.6 - International 4,295 3,961 8.5 4.9 3.6 16,384 15,525 5.5 4.1 1.4 8,801 8,188 7.5 5.8 1.7 33,792 31,857 6.1 5.4 0.7 U.S. 14,195 13,204 7.5 7.5 - 53,752 50,302 6.9 6.9 - International 10,369 9,316 11.3 6.6 4.7 40,441 38,519 5.0 3.4 1.6 Worldwide 24,564 $ 22,520 9.1 % 7.1 2.0 94,193 $ 88,821 6.0 % 5.3 0.7 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. FOURTH QUARTER TWELVE MONTHS Percent Change -- 2 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2025 2024 Total Operations Currency 2025 2024 Total Operations Currency Sales to customers by geographic area U.S. 14,195 $ 13,204 7.5 % 7.5 - 53,752 $ 50,302 6.9 % 6.9 - Europe 5,598 4,921 13.8 5.2 8.6 21,535 20,212 6.5 2.4 4.1 Western Hemisphere excluding U.S. 1,271 1,135 12.0 11.0 1.0 4,875 4,714 3.4 8.4 (5.0) Asia-Pacific, Africa 3,500 3,260 7.4 7.2 0.2 14,031 13,593 3.2 3.1 0.1 International 10,369 9,316 11.3 6.6 4.7 40,441 38,519 5.0 3.4 1.6 Worldwide 24,564 $ 22,520 9.1 % 7.1 2.0 94,193 $ 88,821 6.0 % 5.3 0.7 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. FOURTH QUARTER TWELVE MONTHS Percent Change -- 3 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS INNOVATIVE MEDICINE SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency ONCOLOGY US 3,793 $ 3,019 25.6% 25.6% - 13,659 $ 10,854 25.8% 25.8% - Intl 3,069 2,476 23.9% 17.3% 6.6% 11,721 9,926 18.1% 15.6% 2.5% WW 6,861 5,497 24.8% 21.9% 2.9% 25,380 20,781 22.1% 20.9% 1.2% CARVYKTI US 420 304 38.2% 38.2% - 1,492 869 71.6% 71.6% - Intl 135 31 * * * 395 94 * * * WW 555 334 65.8% 63.2% 2.6% 1,887 963 95.9% 94.3% 1.6% DARZALEX US 2,332 1,799 29.6% 29.6% - 8,266 6,588 25.5% 25.5% - Intl 1,571 1,285 22.3% 16.2% 6.1% 6,085 5,082 19.7% 17.5% 2.2% WW 3,903 3,084 26.6% 24.1% 2.5% 14,351 11,670 23.0% 22.0% 1.0% ERLEADA US 405 342 18.6% 18.6% - 1,453 1,282 13.4% 13.4% - Intl 554 442 25.3% 17.5% 7.8% 2,121 1,717 23.5% 20.1% 3.4% WW 959 784 22.4% 18.0% 4.4% 3,574 2,999 19.2% 17.2% 2.0% IMBRUVICA US 207 250 (17.4)% (17.4)% - 892 1,020 (12.5)% (12.5)% - Intl 478 481 (0.8)% (7.5)% 6.7% 1,931 2,018 (4.3)% (6.7)% 2.4% WW 684 731 (6.5)% (10.9)% 4.4% 2,823 3,038 (7.1)% (8.6)% 1.5% RYBREVANT / LAZCLUZE (3) US 146 101 45.6% 45.6% - 534 257 * * - Intl 70 21 * * * 200 70 * * * WW 216 122 78.0% 76.5% 1.5% 734 327 * * * TALVEY US 105 68 53.8% 53.8% - 340 241 40.9% 40.9% - Intl 44 17 * * * 123 46 * * * WW 149 85 75.8% 73.1% 2.7% 463 287 61.3% 60.3% 1.0% TECVAYLI US 110 108 2.7% 2.7% - 444 418 6.3% 6.3% - Intl 66 38 72.2% 65.1% 7.1% 226 131 72.8% 70.4% 2.4% WW 176 146 20.8% 18.9% 1.9% 670 549 22.1% 21.5% 0.6% ZYTIGA / abiraterone acetate US 5 9 (41.4)% (41.4)% - 23 34 (33.2)% (33.2)% - Intl 115 127 (9.9)% (11.1)% 1.2% 480 597 (19.7)% (20.5)% 0.8% WW 119 135 (11.9)% (13.0)% 1.1% 502 631 (20.4)% (21.2)% 0.8% OTHER ONCOLOGY US 61 39 54.8% 54.8% - 214 145 47.5% 47.5% - Intl 39 36 8.4% 3.0% 5.4% 162 172 (6.0)% (7.8)% 1.8% WW 100 75 32.9% 30.3% 2.6% 376 317 18.5% 17.5% 1.0% See footnotes at end of schedule % Change % Change -- 4 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency IMMUNOLOGY US 2,495 $ 2,856 (12.6)% (12.6)% - 9,872 $ 11,355 (13.1)% (13.1)% - Intl 1,364 1,383 (1.4)% (5.5)% 4.1% 5,856 6,473 (9.5)% (10.2)% 0.7% WW 3,860 4,238 (8.9)% (10.3)% 1.4% 15,728 17,828 (11.8)% (12.0)% 0.2% REMICADE US 248 231 7.1% 7.1% - 1,171 1,009 16.0% 16.0% - US Exports (4) 11 9 17.1% 17.1% - 74 98 (24.8)% (24.8)% - Intl 110 117 (5.6)% (7.3)% 1.7% 523 497 5.3% 6.2% (0.9)% WW 370 359 3.2% 2.6% 0.6% 1,768 1,605 10.2% 10.5% (0.3)% SIMPONI / SIMPONI ARIA US 287 262 9.6% 9.6% - 1,193 1,082 10.3% 10.3% - Intl 345 321 7.4% 3.7% 3.7% 1,475 1,108 33.1% 32.8% 0.3% WW 632 583 8.4% 6.4% 2.0% 2,668 2,190 21.8% 21.7% 0.1% STELARA US 766 1,699 (54.9)% (54.9)% - 3,847 6,720 (42.7)% (42.7)% - Intl 462 650 (28.8)% (32.3)% 3.5% 2,230 3,641 (38.7)% (39.3)% 0.6% WW 1,230 2,349 (47.7)% (48.6)% 0.9% 6,078 10,361 (41.3)% (41.5)% 0.2% TREMFYA US 1,145 654 75.1% 75.1% - 3,529 2,443 44.5% 44.5% - Intl 445 295 50.9% 44.0% 6.9% 1,626 1,227 32.5% 30.4% 2.1% WW 1,589 949 67.6% 65.4% 2.2% 5,155 3,670 40.5% 39.8% 0.7% OTHER IMMUNOLOGY US 39 0 * * - 59 3 * * - Intl 2 0 * * * 2 0 * * * WW 40 0 * * * 61 3 * * * NEUROSCIENCE US 1,439 1,148 25.4% 25.4% - 5,151 4,398 17.1% 17.1% - Intl 675 628 7.6% 4.3% 3.3% 2,686 2,718 (1.2)% (1.8)% 0.6% WW 2,115 1,775 19.1% 17.9% 1.2% 7,837 7,115 10.1% 9.9% 0.2% CAPLYTA (5) US 249 - * * - 700 - * * - Intl - - - - - - - - - - WW 249 - * * - 700 - * * - CONCERTA / Methylphenidate US 6 33 (79.6)% (79.6)% - 82 134 (38.6)% (38.6)% - Intl 126 125 (0.3)% (1.4)% 1.1% 502 507 (1.2)% (0.7)% (0.5)% WW 132 159 (17.1)% (17.8)% 0.7% 584 641 (9.0)% (8.6)% (0.4)% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 704 796 (11.5)% (11.5)% - 2,725 3,125 (12.8)% (12.8)% - Intl 281 267 5.2% 1.9% 3.3% 1,085 1,097 (1.1)% (1.8)% 0.7% WW 986 1,063 (7.3)% (8.2)% 0.9% 3,810 4,222 (9.8)% (9.9)% 0.1% SPRAVATO US 438 269 63.0% 63.0% - 1,485 929 59.9% 59.9% - Intl 64 28 * * * 210 148 41.9% 39.1% 2.8% WW 503 297 69.0% 67.8% 1.2% 1,696 1,077 57.4% 57.0% 0.4% OTHER NEUROSCIENCE US 40 49 (18.3)% (18.3)% - 159 210 (24.5)% (24.5)% - Intl 205 206 (0.7)% (4.3)% 3.6% 889 965 (7.9)% (8.7)% 0.8% WW 245 255 (4.1)% (6.9)% 2.8% 1,048 1,175 (10.9)% (11.5)% 0.6% See footnotes at end of schedule % Change % Change -- 5 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency PULMONARY HYPERTENSION US 865 $ 819 5.7% 5.7% - 3,223 $ 3,143 2.6% 2.6% - Intl 319 274 16.4% 12.2% 4.2% 1,214 1,140 6.5% 4.9% 1.6% WW 1,184 1,092 8.4% 7.4% 1.0% 4,437 4,282 3.6% 3.2% 0.4% OPSUMIT / OPSYNVI US 458 408 11.9% 11.9% - 1,633 1,557 4.8% 4.8% - Intl 185 162 14.8% 10.9% 3.9% 692 668 3.7% 2.1% 1.6% WW 643 570 12.7% 11.6% 1.1% 2,325 2,225 4.5% 4.0% 0.5% UPTRAVI US 397 391 1.6% 1.6% - 1,536 1,511 1.7% 1.7% - Intl 94 75 26.9% 20.8% 6.1% 366 307 19.4% 17.4% 2.0% WW 491 465 5.7% 4.7% 1.0% 1,902 1,817 4.7% 4.3% 0.4% OTHER PULMONARY HYPERTENSION US 10 19 (43.7)% (43.7)% - 54 75 (27.0)% (27.0)% - Intl 39 38 2.6% 1.2% 1.4% 155 165 (6.2)% (6.8)% 0.6% WW 49 57 (12.5)% (13.5)% 1.0% 209 240 (12.7)% (13.0)% 0.3% INFECTIOUS DISEASES US 303 331 (8.5)% (8.5)% - 1,264 1,354 (6.6)% (6.6)% - Intl 505 443 13.9% 5.6% 8.3% 1,977 2,042 (3.2)% (6.5)% 3.3% WW 807 774 4.3% (0.4)% 4.7% 3,241 3,396 (4.6)% (6.5)% 1.9% EDURANT / rilpivirine US 5 7 (39.1)% (39.1)% - 26 31 (18.4)% (18.4)% - Intl 379 315 20.6% 11.1% 9.5% 1,461 1,241 17.7% 13.0% 4.7% WW 383 322 19.2% 9.9% 9.3% 1,486 1,272 16.9% 12.2% 4.7% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 294 321 (8.4)% (8.4)% - 1,226 1,311 (6.5)% (6.5)% - Intl 89 86 3.6% (2.9)% 6.5% 353 401 (11.9)% (13.7)% 1.8% WW 383 407 (5.8)% (7.2)% 1.4% 1,579 1,712 (7.7)% (8.1)% 0.4% OTHER INFECTIOUS DISEASES US 4 1 92.9% 92.9% - 12 11 6.6% 6.6% - Intl 37 43 (14.5)% (18.0)% 3.5% 163 401 (59.3)% (59.5)% 0.2% WW 40 45 (9.9)% (13.2)% 3.3% 175 412 (57.5)% (57.7)% 0.2% CARDIOVASCULAR / METABOLISM / OTHER US 794 805 (1.4)% (1.4)% - 3,175 2,866 10.8% 10.8% - Intl 142 153 (6.3)% (10.7)% 4.4% 603 696 (13.3)% (13.8)% 0.5% WW 936 957 (2.2)% (2.9)% 0.7% 3,778 3,562 6.1% 6.0% 0.1% XARELTO US 687 676 1.7% 1.7% - 2,633 2,373 11.0% 11.0% - Intl - - - - - - - - - - WW 687 676 1.7% 1.7% - 2,633 2,373 11.0% 11.0% - OTHER US 107 130 (17.4)% (17.4)% - 542 494 9.8% 9.8% - Intl 142 153 (6.3)% (10.7)% 4.4% 603 696 (13.3)% (13.8)% 0.5% WW 249 281 (11.4)% (13.8)% 2.4% 1,145 1,189 (3.7)% (4.0)% 0.3% TOTAL INNOVATIVE MEDICINE US 9,689 8,977 7.9% 7.9% - 36,344 33,970 7.0% 7.0% - Intl 6,074 5,355 13.4% 7.9% 5.5% 24,057 22,994 4.6% 2.9% 1.7% WW 15,763 $ 14,332 10.0% 7.9% 2.1% 60,401 $ 56,964 6.0% 5.3% 0.7% See footnotes at end of schedule % Change % Change -- 6 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS MEDTECH SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency CARDIOVASCULAR US 1,374 $ 1,221 12.5% 12.5% - 5,305 $ 4,513 17.5% 17.5% - Intl 925 841 10.1% 6.8% 3.3% 3,623 3,194 13.4% 11.9% 1.5% WW 2,299 2,062 11.5% 10.1% 1.4% 8,928 7,707 15.8% 15.2% 0.6% ELECTROPHYSIOLOGY US 746 681 9.5% 9.5% - 2,891 2,738 5.6% 5.6% - Intl 679 640 6.2% 3.2% 3.0% 2,743 2,529 8.5% 7.3% 1.2% WW 1,425 1,321 7.9% 6.5% 1.4% 5,634 5,267 7.0% 6.4% 0.6% ABIOMED US 358 308 16.5% 16.5% - 1,393 1,213 14.9% 14.9% - Intl 102 77 33.1% 25.4% 7.7% 358 284 26.4% 22.0% 4.4% WW 460 384 19.8% 18.3% 1.5% 1,751 1,496 17.1% 16.2% 0.9% SHOCKWAVE US 238 202 18.0% 18.0% - 897 442 * * - Intl 80 56 42.3% 40.7% 1.6% 249 122 * * * WW 318 258 23.3% 22.9% 0.4% 1,146 564 * * * OTHER CARDIOVASCULAR US 31 31 (0.1)% (0.1)% - 124 120 3.1% 3.1% - Intl 64 68 (6.7)% (8.8)% 2.1% 273 260 4.9% 4.1% 0.8% WW 95 99 (4.6)% (6.1)% 1.5% 397 380 4.3% 3.8% 0.5% ORTHOPAEDICS US 1,520 1,460 4.2% 4.2% - 5,720 5,689 0.5% 0.5% - Intl 918 856 7.3% 2.3% 5.0% 3,538 3,470 2.0% (0.2)% 2.2% WW 2,438 2,315 5.3% 3.5% 1.8% 9,258 9,158 1.1% 0.3% 0.8% HIPS US 284 272 4.3% 4.3% - 1,080 1,057 2.1% 2.1% - Intl 154 146 5.5% 0.4% 5.1% 594 581 2.2% 0.1% 2.1% WW 439 418 4.7% 2.9% 1.8% 1,674 1,638 2.1% 1.4% 0.7% KNEES US 251 238 5.1% 5.1% - 924 922 0.2% 0.2% - Intl 181 160 13.7% 9.2% 4.5% 663 623 6.5% 4.6% 1.9% WW 432 398 8.6% 6.8% 1.8% 1,587 1,545 2.7% 2.0% 0.7% TRAUMA US 543 514 5.6% 5.6% - 2,058 2,013 2.2% 2.2% - Intl 270 250 7.9% 2.7% 5.2% 1,088 1,036 5.0% 2.7% 2.3% WW 813 764 6.4% 4.7% 1.7% 3,146 3,049 3.2% 2.4% 0.8% SPINE, SPORTS & OTHER US 442 434 1.9% 1.9% - 1,658 1,696 (2.2)% (2.2)% - Intl 312 300 4.2% (0.7)% 4.9% 1,193 1,230 (3.0)% (5.3)% 2.3% WW 756 735 2.8% 0.8% 2.0% 2,852 2,926 (2.5)% (3.5)% 1.0% See footnotes at end of schedule % Change % Change -- 7 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency SURGERY US 1,081 $ 1,038 4.2% 4.2% - 4,157 $ 4,003 3.9% 3.9% - Intl 1,563 1,469 6.4% 3.4% 3.0% 5,980 5,842 2.4% 1.5% 0.9% WW 2,644 2,507 5.5% 3.7% 1.8% 10,137 9,845 3.0% 2.5% 0.5% ADVANCED US 489 478 2.5% 2.5% - 1,900 1,838 3.4% 3.4% - Intl 687 673 1.9% (0.8)% 2.7% 2,678 2,650 1.0% 0.1% 0.9% WW 1,175 1,151 2.2% 0.6% 1.6% 4,577 4,488 2.0% 1.5% 0.5% GENERAL US 592 560 5.6% 5.6% - 2,258 2,165 4.3% 4.3% - Intl 876 795 10.2% 6.9% 3.3% 3,302 3,192 3.4% 2.7% 0.7% WW 1,468 1,357 8.3% 6.3% 2.0% 5,560 5,358 3.8% 3.3% 0.5% VISION US 531 509 4.3% 4.3% - 2,225 2,128 4.6% 4.6% - Intl 889 794 11.9% 8.5% 3.4% 3,243 3,018 7.4% 5.9% 1.5% WW 1,420 1,303 8.9% 6.8% 2.1% 5,468 5,146 6.3% 5.3% 1.0% CONTACT LENSES / OTHER US 417 396 5.3% 5.3% - 1,754 1,684 4.1% 4.1% - Intl 592 541 9.3% 5.3% 4.0% 2,157 2,049 5.3% 3.2% 2.1% WW 1,008 937 7.6% 5.3% 2.3% 3,910 3,733 4.8% 3.6% 1.2% SURGICAL US 113 113 0.6% 0.6% - 471 444 6.1% 6.1% - Intl 297 252 17.7% 15.3% 2.4% 1,086 969 12.1% 11.6% 0.5% WW 411 365 12.4% 10.8% 1.6% 1,558 1,413 10.2% 9.9% 0.3% TOTAL MEDTECH US 4,506 4,227 6.6% 6.6% - 17,408 16,332 6.6% 6.6% - Intl 4,295 3,961 8.5% 4.9% 3.6% 16,384 15,525 5.5% 4.1% 1.4% WW 8,801 $ 8,188 7.5% 5.8% 1.7% 33,792 $ 31,857 6.1% 5.4% 0.7% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE (4) Reported as U.S. sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely % Change % Change -- 8 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 24,564 $ 100.0 22,520 $ 100.0 9.1 Cost of products sold 7,968 32.4 7,128 31.6 11.8 Gross Profit 16,596 67.6 15,392 68.4 7.8 Selling, marketing and administrative expenses 6,753 27.5 6,453 28.6 4.6 Research and development expense 4,252 17.3 5,298 23.5 (19.7) In-process research and development impairments 81 0.3 17 0.1 Interest (income) expense, net (23) (0.1) (144) (0.6) Other (income) expense, net 483 2.0 (161) (0.7) Restructuring 84 0.4 42 0.2 Earnings before provision for taxes on income 4,966 20.2 3,887 17.3 27.8 (Benefit from)/Provision for taxes on income (150) (0.6) 456 2.1 (132.9) Net earnings 5,116 $ 20.8 3,431 $ 15.2 49.1 Net earnings per share (Diluted) 2.10 $ 1.41 $ 48.9 Average shares outstanding (Diluted) 2,439.0 2,427.1 Effective tax rate (3.0) % 11.7 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 7,046 $ 28.7 5,421 $ 24.1 30.0 Net earnings 6,009 $ 24.5 4,946 $ 22.0 21.5 Net earnings per share (Diluted) 2.46 $ 2.04 $ 20.6 Effective tax rate 14.7 % 8.8 % (1) See Reconciliation of Non-GAAP Financial Measures. FOURTH QUARTER 2025 2024 -- 9 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 94,193 $ 100.0 88,821 $ 100.0 6.0 Cost of products sold 30,256 32.1 27,471 30.9 10.1 Gross Profit 63,937 67.9 61,350 69.1 4.2 Selling, marketing and administrative expenses 23,676 25.1 22,869 25.7 3.5 Research and development expense 14,665 15.6 17,232 19.4 (14.9) In-process research and development impairments 81 0.1 211 0.2 Interest (income) expense, net (85) (0.1) (577) (0.6) Other (income) expense, net (7,209) (7.6) 4,694 5.3 Restructuring 228 0.2 234 0.3 Earnings before provision for taxes on income 32,581 34.6 16,687 18.8 95.2 Provision for taxes on income 5,777 6.1 2,621 3.0 120.4 Net earnings 26,804 $ 28.5 14,066 $ 15.8 90.6 Net earnings per share (Diluted) 11.03 $ 5.79 $ 90.5 Average shares outstanding (Diluted) 2,429.4 2,429.4 Effective tax rate 17.7 % 15.7 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 31,681 $ 33.6 28,979 $ 32.6 9.3 Net earnings 26,215 $ 27.8 24,242 $ 27.3 8.1 Net earnings per share (Diluted) 10.79 $ 9.98 $ 8.1 Effective tax rate 17.3 % 16.3 % (1) See Reconciliation of Non-GAAP Financial Measures. TWELVE MONTHS 2025 2024 -- 10 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 10.0% 7.5% 9.1% U.S. 7.9% 6.6% 7.5% International 13.4% 8.5% 11.3% WW Currency 2.1 1.7 2.0 U.S. - - - International 5.5 3.6 4.7 WW Operational 7.9% 5.8% 7.1% U.S. 7.9% 6.6% 7.5% International 7.9% 4.9% 6.6% Caplyta (1.7) (1.1) U.S. (2.8) (1.9) International 0.0 0.0 All Other Acquisitions and Divestitures (A&D) 0.0 0.1 0.1 U.S. 0.0 0.1 0.1 International 0.1 0.2 0.2 WW Adjusted Operational Ex A&D 6.2% 5.9% 6.1% U.S. 5.1% 6.7% 5.7% International 8.0% 5.1% 6.8% Adjusted Operational Sales Growth FOURTH QUARTER 2025 ACTUAL vs. 2024 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 11 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 6.0% 6.1% 6.0% U.S. 7.0% 6.6% 6.9% International 4.6% 5.5% 5.0% WW Currency 0.7 0.7 0.7 U.S. - - - International 1.7 1.4 1.6 WW Operational 5.3% 5.4% 5.3% U.S. 7.0% 6.6% 6.9% International 2.9% 4.1% 3.4% Shockwave (1.4) (0.5) U.S. (2.1) (0.7) International (0.5) (0.2) Caplyta (1.2) (0.7) U.S. (2.1) (1.4) International 0.0 0.0 All Other Acquisitions and Divestitures (A&D) 0.0 0.3 0.1 U.S. 0.0 0.3 0.1 International 0.1 0.2 0.1 WW Adjusted Operational Ex A&D 4.1% 4.3% 4.2% U.S. 4.9% 4.8% 4.9% International 3.0% 3.8% 3.3% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth TWELVE MONTHS 2025 ACTUAL vs. 2024 ACTUAL Segments -- 12 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2025 2024 2025 2024 Net Earnings, after tax- as reported $5,116 $3,431 $26,804 $14,066 Pre-tax Adjustments Litigation related 854 (16) (6,040) 5,450 Intangible Asset Amortization expense 1,186 1,171 4,621 4,526 Restructuring related 1 210 62 512 269 Acquisition, integration and divestiture related (190) 298 285 1,226 IPR&D impairments 81 17 81 211 (Gains)/losses on securities (100) (68) (427) 306 Orthopaedics Separation related 48 - 48 - COVID-19 Vaccine related costs - 23 - 100 Medical Device Regulation - 47 - 204 Other (9) - 20 - Tax Adjustments Tax impact on special item adjustments 2 (445) (80) 381 (2,135) Tax legislation and other tax related (742) 61 (70) 19 Adjusted Net Earnings, after tax $6,009 $4,946 $26,215 $24,242 Average shares outstanding (Diluted) 2,439.0 2,427.1 2,429.4 2,429.4 Adjusted net earnings per share (Diluted) $2.46 $2.04 $10.79 $9.98 Operational adjusted net earnings per share (Diluted) $2.35 $10.58 Notes: 1 2 Fourth Quarter Twelve Months Ended In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million in fiscal 2024 included the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $162 million in the fiscal fourth quarter of 2025 ($307 million Q4 2025 YTD) and $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025. In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $48 million in the fiscal fourth quarter of 2025 ($205 million Q4 2025 YTD) primarily includes costs related to asset impairments and market and product exits. This program is expected to be substantially completed by the end of fiscal year 2026. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. -- 13 of 17 -- Innovative Medicine Fourth Quarter Dec. 28, 2025 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Other Fourth Quarter Dec. 28, 2025 Non-GAAP Cost of products sold 3,976 $ (704) (11) 3,261 Selling, marketing and admin expenses 3,456 3,456 Research and development expense 3,466 3,466 Other segment items (193) 16 (11) (52) 101 4 (135) Adjusted Income Before Tax by Segment 5,058 704 (16) 11 - 63 (101) - - (4) 5,715 MedTech Fourth Quarter Dec. 28, 2025 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Other Fourth Quarter Dec. 28, 2025 Non-GAAP Cost of products sold 3,973 $ (482) (56) 3,435 Selling, marketing and admin expenses 3,035 3,035 Research and development expense 786 786 Other segment items 806 (818) (70) (154) 290 (1) (48) 5 10 Adjusted Income Before Tax by Segment 201 482 818 70 210 (290) 1 48 - (5) 1,535 Expenses not allocated to segments Fourth Quarter Dec. 28, 2025 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Other Fourth Quarter Dec. 28, 2025 Non-GAAP Cost of products sold 19 $ 19 Selling, marketing and admin expenses 262 262 Research and development expense - - Other segment items 12 (52) (37) (77) Adjusted Income Before Tax by Segment (293) - 52 - - 37 - - - - (204) Johnson & Johnson Consolidated Fourth Quarter Dec. 28, 2025 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Other Fourth Quarter Dec. 28, 2025 Non-GAAP Cost of products sold 7,968 $ (1,186) (56) (11) 6,715 Selling, marketing and admin expenses 6,753 6,753 Research and development expense 4,252 4,252 Other (Income) / Expense 483 (854) (70) 201 100 (48) 9 (179) In-process research and development impairments 81 (81) - Interest (Income)/Expense (23) (23) Restructuring 84 (84) - Adjusted Income Before Tax 4,966 1,186 854 81 210 (190) (100) 48 - (9) 7,046 Provision for taxes on income (150) 226 32 18 35 149 (23) 11 742 (3) 1,037 Net Earnings 5,116 $ 960 822 63 175 (339) (77) 37 (742) (6) 6,009 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date -- 14 of 17 -- Innovative Medicine Fourth Quarter Dec. 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Fourth Quarter Dec. 29, 2024 Non-GAAP Cost of products sold 3,514 $ (685) 2,829 Selling, marketing and admin expenses 3,312 3,312 Research and development expense 3,698 (6) 3,692 Other segment items (201) 41 (17) (2) (12) 50 (17) (158) Adjusted Income Before Tax by Segment 4,009 685 (41) 17 2 12 (50) - 23 - 4,657 MedTech Fourth Quarter Dec. 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Fourth Quarter Dec. 29, 2024 Non-GAAP Cost of products sold 3,596 $ (477) (20) (153) (18) 2,928 Selling, marketing and admin expenses 2,836 (4) 2,832 Research and development expense 1,600 (25) 1,575 Other segment items 84 (9) 29 (40) (115) 18 (33) Adjusted Income Before Tax by Segment 72 486 (29) - 60 268 (18) 47 - - 886 Expenses not allocated to segments Fourth Quarter Dec. 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Fourth Quarter Dec. 29, 2024 Non-GAAP Cost of products sold 18 $ 18 Selling, marketing and admin expenses 305 305 Research and development expense - - Other segment items (129) (54) (18) (201) Adjusted Income Before Tax by Segment (194) - 54 - - 18 - - - - (122) Johnson & Johnson Consolidated Fourth Quarter Dec. 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Fourth Quarter Dec. 29, 2024 Non-GAAP Cost of products sold 7,128 $ (1,162) (20) (153) (18) 5,775 Selling, marketing and admin expenses 6,453 (4) 6,449 Research and development expense 5,298 (25) (6) 5,267 Other (Income) / Expense (161) (9) 16 (145) 68 (17) (248) In-process research and development impairments 17 (17) - Interest (Income)/Expense (144) (144) Restructuring 42 (42) - Adjusted Income Before Tax 3,887 1,171 (16) 17 62 298 (68) 47 23 - 5,421 Provision for taxes on income 456 171 (158) 4 3 80 (34) 9 5 (61) 475 Net Earnings 3,431 $ 1,000 142 13 59 218 (34) 38 18 61 4,946 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date -- 15 of 17 -- Year to Date Innovative Medicine Twelve Months Dec. 28, 2025 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Other Twelve Months Dec. 28, 2025 Non-GAAP Cost of products sold 15,646 $ (2,706) (35) 12,905 Selling, marketing and admin expenses 11,375 11,375 Research and development expense 11,827 11,827 Other segment items (713) 90 (11) (327) 265 (10) (706) Adjusted Income Before Tax by Segment 22,266 2,706 (90) 11 - 362 (265) - - 10 25,000 MedTech Twelve Months Dec. 28, 2025 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Other Twelve Months Dec. 28, 2025 Non-GAAP Cost of products sold 14,549 $ (1,915) (91) (52) 12,491 Selling, marketing and admin expenses 11,354 11,354 Research and development expense 2,838 37 2,875 Other segment items 938 (896) (70) (421) 135 162 (48) (10) (210) Adjusted Income Before Tax by Segment 4,113 1,915 896 70 512 (120) (162) 48 - 10 7,282 Expenses not allocated to segments Twelve Months Dec. 28, 2025 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Other Twelve Months Dec. 28, 2025 Non-GAAP Cost of products sold 61 $ 61 Selling, marketing and admin expenses 947 947 Research and development expense - - Other segment items (7,210) 6,846 (43) (407) Adjusted Income Before Tax by Segment 6,202 - (6,846) - - 43 - - - - (601) Johnson & Johnson Consolidated Twelve Months Dec. 28, 2025 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Other Twelve Months Dec. 28, 2025 Non-GAAP Cost of products sold 30,256 $ (4,621) (91) (87) 25,457 Selling, marketing and admin expenses 23,676 23,676 Research and development expense 14,665 37 14,702 Other (Income) / Expense (7,209) 6,040 (193) (235) 427 (48) (20) (1,238) In-process research and development impairments 81 (81) - Interest (Income)/Expense (85) (85) Restructuring 228 (228) - Adjusted Income Before Tax 32,581 4,621 (6,040) 81 512 285 (427) 48 - 20 31,681 Provision for taxes on income 5,777 829 (1,509) 18 93 267 (96) 11 70 6 5,466 Net Earnings 26,804 $ 3,792 (4,531) 63 419 18 (331) 37 (70) 14 26,215 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions -- 16 of 17 -- Innovative Medicine Twelve Months Dec. 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Twelve Months Dec. 29, 2024 Non-GAAP Cost of products sold 14,036 $ (2,772) (8) 11,256 Selling, marketing and admin expenses 10,906 10,906 Research and development expense 13,529 (25) 13,504 Other segment items (426) (358) (211) (102) (66) 76 (67) (1,154) Adjusted Income Before Tax by Segment 18,919 2,772 358 211 102 66 (76) - 100 - 22,452 MedTech Twelve Months Dec. 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Twelve Months Dec. 29, 2024 Non-GAAP Cost of products sold 13,345 $ (1,745) (35) (359) (84) 11,122 Selling, marketing and admin expenses 10,812 (16) 10,796 Research and development expense 3,703 (69) (104) 3,530 Other segment items 257 (9) 14 (132) (587) (30) (487) Adjusted Income Before Tax by Segment 3,740 1,754 (14) - 167 1,015 30 204 - - 6,896 Expenses not allocated to segments Twelve Months Dec. 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Twelve Months Dec. 29, 2024 Non-GAAP Cost of products sold 90 $ 90 Selling, marketing and admin expenses 1,151 1,151 Research and development expense - - Other segment items 4,731 (5,106) (145) (352) (872) Adjusted Income Before Tax by Segment (5,972) - 5,106 - - 145 352 - - - (369) Johnson & Johnson Consolidated Twelve Months Dec. 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Twelve Months Dec. 29, 2024 Non-GAAP Cost of products sold 27,471 $ (4,517) (35) (359) (84) (8) 22,468 Selling, marketing and admin expenses 22,869 (16) 22,853 Research and development expense 17,232 (69) (104) (25) 17,034 Other (Income) / Expense 4,694 (9) (5,450) (798) (306) (67) (1,936) In-process research and development impairments 211 (211) - Interest (Income)/Expense (577) (577) Restructuring 234 (234) - Adjusted Income Before Tax 16,687 4,526 5,450 211 269 1,226 306 204 100 - 28,979 Provision for taxes on income 2,621 644 1,066 47 45 302 (29) 38 22 (19) 4,737 Net Earnings 14,066 $ 3,882 4,384 164 224 924 335 166 78 19 24,242 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Year to Date -- 17 of 17 --